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Abstract
Background: The local treatment of burn wounds has long been a subject of debate. The objective of this study
was to compare the cost and the effectiveness of Moist Exposed Burn Ointment -MEBO versus a combination of
povidone iodine plus bepanthenol cream for partial thickness burns.
Methods: The study was carried out in the Burn Center of a state hospital in Athens, Greece. 211 patients needing
conservative therapy were prospectively selected according to the depth of the burn wound. The treatment was
allocated according to the Stratified Randomization Design. The outcomes measured were mean cost of in-hospital
stay, rate of complications, time of 50% wound healing, pain scores, in hospital stay diminution. We have adopted
a societal perspective.
Results: In the total groups MEBO presented lower cost, (although not significantly different: p = 0.10) and better
effectiveness. The data suggest that MEBO is the dominant therapy for superficial partial burn wound with
significantly lower costs and significantly higher effectiveness due to a lesser time of recovery and consequently
lower time of hospitalization and follow-up. MEBO presented similar percentages of complications with the
comparator, lower pain levels and smaller time of no healthy appearance of the burn limits for superficial partial
thickness burns.
Conclusions: The data suggested that topical application of MEBO may be considered for further investigation as
a potential first-line treatment modality for superficial partial thickness burns.
Trial registration: The trial has been registered on the International Standard Randomised Controlled Trial Number
Register (ISRCTN) and given the registration number ISRCTN74058791.
Background
The local treatment of burn wounds has long been a
subject of debate. Several agents in many forms (creams,
dressings, gauzes etc.) have been applied to improve and
accelerate the healing process [1]. Management of the
burn wounds with natural products like herbs (tea tree,
aloe vera, shea butter), or animal products (honey, emu
oil) is also a worldwide common practice.
Moist exposed burn ointment (MEBO) is an oil-based
ointment that contains sesame oil, beta-sitosterol, ber-
berine, and other small quantities of plant ingredients
[2] developed at the China National Science and Tech-
nology Centre in Beijing in 1989 [3]. The main ingredi-
ent of MEBO is beta-sitosterol, which has been shown
to have anti-inflammatory effects, [4] and berberine,
which has antimicrobial effects [4]. Laboratory tests
have indicated that MEBO was not a mucocutaneous
irritant nor was it orally toxic to rats; repeated cuta-
neous patch tests in humans did not show any potential
for dermal irritation or sensitization [5]. Clinical and
experimental investigations have shown that MEBO has
analgesic and antimicrobial effects, and reduces water
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dies have found that MEBO promotes debridement,
epithelial repair and is associated with better scar quality
[6-17]. In three consecutively conducted clinical studies,
Atiyeh et al., found that the MEBO exhibited a benefi-
cial prophylactic effect on primary and secondary
wound healing with scar quality superior in wounds
treated with MEBO [10.11.15]. In a prospective com-
parative study comparing healing with MEBO to con-
ventional occlusive dressings, the biologic healing with
MEBO, as determined by trans-epidermal water loss
(TEWL) measurements, occurred at an extremely signif-
icant earlier stage and was associated with better scar
quality [16].
Although there is an important number of a consider-
able study in the Chinese language [18-26] regarding the
safety and the effectiveness of MEBO, few are the stu-
dies evaluating this alternative therapy worldwide. It is
pointed out that there is a poor record of Trial Based
Economic Evaluations comparing MEBO [5-7]. Informa-
tion for these studies is given on Table 1.
Methods
Aims of the trial
This study is the first conducted in Greece comparing
these therapies. The aim of this trial is to test the
hypothesis that MEBO substantially reduces the time of
wound healing and is the more cost effective treatment
modality for the local treatment of partial thickness
burns compared to the standard practice. Specifically,
we aimed at testing the hypotheses of treating partial
thickness burns with MEBO:
i. Reduces hospitalization time and wound healing
[10-17]
ii. Reduces recovery costs [11,12].
iii. Reduces pain levels [10-12]
iv. Does not increase complication rates [10-12]
Study population
The patient inclusion criteria were: 1. absence of cancer
and diabetes 2. Total Burns Surface Area (TBSA) < 15%.
3. Thermal burns 4. No need of surgical operation 5.
Need for hospitalization. 211 (214 randomized) patients,
Table 1 Principal characteristics of Trial Based Economic Evaluations comparing MEBO.
Author
and
country
Patient group Study type, setting and
perspective
Comparators Main results
1) Ang et
al, 2001
Singapore
115 (started) patients (6-80 years)
with partial thickness (TBSA: <
40%) burns to the face excluding
chemical and electrical burns.
Cost consequences, single
centre study, secondary care.
Perspective adopted: health
care system
Silver sulfadiazine cream (C) The median time to 75% healing
was 17.0 and 20.0 days in MEBO
and conventional therapy groups,
respectively (Hazard Ratio: HR:
0.67; 95% CI: 0.41-1.11; p = 0.11),
(similar efficacy). Bacterial
infection rates were similar
between the two groups (HR:
1.10; 95% CI: 0.59-2.03; p = 0.76).
MEBO imparted a greater
analgesic effect in the first 5 days
of therapy and reduced hospital
costs by 8%
2) Atiyeh
B. S. et al,
Egypt,
2002
40 patients between (5-54 years)
with superficial partial thickness
burns 5-20% TBSA in adults and
5-15% TBSA in children,
excluding chemical and electrical
burns and patients with visual,
mental or physical disabilities
pregnant or lactating women as
females at pregnancy risk.
Cost Benefit under a clinical
prospective multi-center (five
centers) study, secondary care.
Perspective adopted: health
care system
Silver sulphadiazine, Sofratulle
Chlorhexidinetulle, Nitrofurazone,
Quadriderm (betamethasone +
chlorocresol+clioquinol
+gentamicin+tolnaftate),
Dexpanthenol,
NitrofurazoneSavlon (cetrimide +
chlorhexidine) Hydrogen
peroxide Povidone-iodine
Patients not treated with MEBO
application required statistically
significant (p < 0.01) longer
hospitalization. (30%) The time
spent by nurses (p < 0.01) and
doctors (p < 0.05), were
significantly lower in MEBO as
well as overall direct costs (p <
0.01.)
3) Atiyeh
B. S. et
al., 2004,
Saudi
Arabia
52 (started) patients (2-58 years)
with a second degree TBSA
burns of 5 to 35% burn (> 15%
TBSA for children and > 20% for
adults), excluding chemical and
electrical burns
Cost consequences under a
clinical prospective multi-
center (14 centers) study,
secondary care. Perspective
adopted: health care system
Silver Sulfadiazine, Extract cepae
10%, heparin sodium 5000 iu
and allantion, Panothenic acid,
Chlorohexidine, Fucidic acid
Bacitracin zinc and neomycin
sulphate, Povidone iodine,
Sofratulle.
Significant differences in favour of
MEBO group concerning the
reduction of 20.24% in
hospitalization time (p = 0.0056),
the total hospitalization cost (p =
0.025), the total time spent by
physicians and nurses, the
analgesic cost per day reduced
by 60.8%) per course (p = 0.0135)
and 55.88% per day (p = 0.0271).
The other differences aren’t
significant.
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Page 2 of 16aged between 18-75 years were prospectively selected.
Three patients were excluded because of violation of the
inclusion criteria (need of surgical operation). The flow
of the participants is described in Figure 1.
Study design and protocol
Randomization
The research was carried out in “G.Gennimatas”,t h e
Regional General Hospital of Athens, Clinic of Plastic
Surgery. The evaluation was carried out under a society
perspective. We compared MEBO with the combination
of povidone iodine plus bepanthenol cream (standard
therapy). The reason for selecting Povidone iodine as
comparator was based on the fact that in Greece, up to
this day, it is the standard practice of therapy for burns
of this kind. The setting of our study used Povidone
Iodine solution followed by some moisturizing, healing
promoting cream (mainly bepanthenol cream) as a stan-
dard burn wound treatment.
We opted for stratified randomization [26] according
to the thickness degree to prevent large imbalances. In
each therapy group we had 2 sub groups according to
the thickness degree:
1) Patients with superficial partial thickness burns who
attracted the greatest interest because of an application
possibility of the indicator Transepidermal Water Loss
  
      
Assessed for eligibility: n=214
Excluded  n=3
(no meeting of inclusion criteria)
Randomized n=211
Allocated to 
MEBO
n=104
Allocated to 
STANDARD 
THERAPY
n=107
Deep partial 
thickness burns
n=50
Discontinued 
therapy because 
of allergy n=3
Superficial partial 
thickness burns
n=54
Discontinued 
therapy because 
of allergy n=2
Deep partial 
thickness 
burns
n=52
Superficial 
partial thickness 
burns
n=55
MEBO
n=106
STANDARD 
THERAPY
n=108
Analyzed
n=50
Analyzed
n=54
Analyzed
n=52
Analyzed
n=55
Figure 1 Participant flow through the trial.
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the patients presenting Transepidermal Water Loss < 60
gr/m
2/h in the first day.
2. Patients with deep partial thickness burns, present-
ing (Transepidermal Water Loss -TEWL ≥ 60 gr/m
2/h.
The follow up duration was 18 days.
The procedures followed in the study were in accor-
dance with the recognized ethical standards and with
the Helsinki Declaration. The protocol of the study was
approved by the Scientific Committee of General Regio-
nal Hospital of Athens. The patients provided written
consent for participation prerandomization after they
were given a full explanation of the treatment options
and the manner of treatment allocation. The allocation
was carried out by the staff of outpatient reception desk
of the Clinic. Patient Envelopes were provided for
patients requiring treatment allocation in each group.
These were numbered sequentially and a list was pro-
vided with the envelopes and completed with the trial
number and patient name. The date when the envelope
was opened (i.e., the date of randomization) was added.
Randomly, alteration was used of permuted 20 sub-
blocks of sizes from 1-3 for deep partial thickness burns
group and 25 sub-blocs of the same size for the superfi-
cial partial burn groups. Blinding the treatments was
not possible because Povidone iodine has a characteris-
t i cc o l o ra n do d o r .B l i n d i n gw a sm a d eo n l yf o rp e r s o n s
evaluating treatment outcomes in order to eliminate
classification bias.
Wound care
The local agents- MEBO and Povidone Iodine -, were
applied twice per day by the assistance of nursing per-
sonnel. Bepanthenol cream was self-applied or by assis-
tance of the nursing personnel. It was applied twice per
day after the third or fourth day of therapy with povi-
done iodine according to the degree of re-epithelializa-
tion. The burn wounds (both groups) were also treated
and lightly debrided by antiseptic in the shower every
second day by the nursing staff, or by medical person-
nel. Also, dressing of the burn wounds during hospitali-
zation was not applicable primarily because of
considerable shortcomings in nursing personnel. That is
in the Clinic of Plastic Surgery of the Regional General
Hospital of Athens “G. Gennimatas”, the open technique
was used for the burn wounds and required less medical
care and was less expensive in terms of hospitalization
cost.
Primary clinical outcomes
The measured outcomes were:
1. For all groups of patients the mean reduction- in
days- of in-hospital stay (standard of sojourn according
to the experts: = 10 days) [27]. That is, the one therapy
was more effective than the other, if it allowed for
greater gain in hospitalization days than the other ther-
apy did.
2. For patients with superficial partial thickness burns,
the time of recovery using the TEWL indicator by con-
sidering as recovery the 50% diminution of the TEWL
of the first day. The use of 2 different effectiveness mea-
sures was justified by the fact that TEWL indicator
wasn’t valid in the case of deep partial thickness burns.
Doctors utilized TEWL indicator measurement habi-
tually on 1
st,4
th,a n d7
th day and after discharge during
the visits.
Costs
The cost measured was the cost of in-hospital stay
including the cost of medicines and of biochemical
examinations and, after discharge, the cost per medical
visit and cost per medicines. These costs reflected the
full economic costs for the National Health Service and
the patients. Also, the time of hospitalization constituted
the time of incapacity for work with direct social impli-
cations. The reference year was 2006. Additionally, the
total times spent per course by doctors and nurses were
calculated and evaluated independently [28].
The cost is described analytically on Table 2. No dis-
count rate was applied, as the study period for each par-
ticipant was < 1 year. Other costs such as interviews by
phone were excluded because of their low impact on
the costs. Other indirect costs such as travel time and
waiting time were trivially small and did not differ
across regimens and consequently their inclusion would
have no important effect on the final results ("rule of
reason criterion”) [28].
No other measurements of production and productiv-
i t yl o s s e sw e r em a d eb e c a u s eo fn op r o v i s i o no ft h e s e
approaches for taking into account unpaid work, in par-
ticular domestic work, or the time of those not in active
employment [28]. Such were the cases of retired persons
(15 out of 104 in the MEBO group, 16 out of 107 in the
standard therapy group) unemployed (1 out of 104, 3
out of 107), housework persons (3 out of 104, 2 out of
107).
Incremental Cost effectiveness
The formula for the incremental cost effectiveness ratio
of the new therapy N versus the existing therapy S (μC
and μE being the mean cost and the mean final out-
comes effectiveness) is given below:
ICER =
μCN − μCS
μEN − μES
=
μ C
μ E
where x expresses the point estimation of parameter
x,
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The intermediate consequences measured were:
a. Pain: All patients were assessed for pain by a regis-
tered doctor immediately prior to randomization. A
visual analogue scale from 1 to 10 was used: 0 = no
pain; 1-2 = slight pain; 3-4 = mild pain; 5 = moderate
pain; 6-9 = moderately severe pain; 10 = severe pain
[11]. Pain scores were recorded twice daily by the doc-
tors. Pain medication was given upon patient demand.
b. Clinical evaluation of the appearance of burn limits
A clinical evaluation of the appearance of burn limits
was made each day by the doctor. We used a binary and
a continuous variable to quantify these criteria. The
modalities of the first variable were: 1. Healthy appear-
ance of burn limits. 2. No Healthy appearance (present-
ing Redness, Swelling, Other). The choice of a binary
variable was due to the lack of instruments that aggre-
gated the extent of trouble caused by each type of no
h e a l t h ya p p e a r a n c e .T h eo t h e rv a r i a b l ew a st h et i m eo f
no healthy appearance during the follow up.
c. Percentage of complications. We compared the per-
centage of complications that appeared during the treat-
ment, (allergy and infection), in total groups and
subgroups.
After discharge from the hospital the observation of
patients concerning the pain and the burn limits was
achieved through consultation and by the doctor’sp e r -
sonal contact on the telephone.
Statistical issues
Data imperfections
No patients refused to participate in the study. As
referred to above, three patients were excluded of the
study because of eligibility errors (un-reordered data).
These eligibility errors did not create bias because the
eligibility criteria of the study were defined objectively
before treatment allocation [26]. There weren’t censored
observations for the final outcomes. We did have loss of
contact for the pain measurement (9th day and after)
for 3 patients recovered earlier than 8th day (1 for the
MEBO group and 2 for the old therapy group). These
censored observations were imputed by the Method of
Last Observation Carried Forward, with decreased risk
of bias because the censoring occurred near the end of
the follow-up period [26].
Protocol induced costs and outcomes
Although the design of this study was pragmatically
oriented, protocol induced outcomes were observed in
the case of superficial partial MEBO group. Prolongation
of in- hospital stay by 4-5 days was observed in the
beginning of the study (despite the suggestions of the
blinded evaluator), for six patients in order to measure
Table 2 Costs per patient generated during hospitalisation and after discharge (2006 prices)
Cost type Health service type Unit Quantity Cost per patient (€)
In hospital costs Hospitalization Day 1 73.37
Time spent by personnel and
nurses
Course of treatment 1 No standardized (in minutes)
Medicine Sodium Fluoride 1000 ml 0.74 per day*1 day
Medicine Povidone iodine scrub 1000 ml 3.65 integral cost price
Medicine Tears natural 0.6 ml 0.18 per day
Medicine Povidone iodine solution 240 ml 1.24 integral cost price
In hospital costs and after
discharge
Medicine MEBO 45 ml 10.00 integral cost proposed
price
Medicine Bepanthenol cream 100 gr 6.78 integral cost price
Medicine Paracetamol (500 gr) 0.34 integral cost price
Medicine Paracetamol plus Codeine (400 mg+50
mg)
0.31 integral cost price
Physician’s visit Visit 1 3.00
Additional in-hospital costs of
events
Laboratory tests Antibiogramm 1 5.22
Laboratory tests Biochemical examinations 1 5.22
Medicine Ciprofloraxine, (Vial) 200 mg 2 * €14.49*8 days
Medicine Ammoxycillin, (Vial) 1 gr 3* €1.17*8 days
Medicine Ammoxyciline+Clavulanic acid
(Vial)
600 mg 3* €1.49 *8 days
Medicine Clindamycine (Vial) 600 mg 2*8.20 *8 days
Medicine Cefotaxim (Vial) 500 mg 2*€1.88 *8 days
Medicine Dimethindene (cream) 30 gr 1.53 integral cost price
Medicine Methylprednisonole (Vial) 1 gr 7.42 per day
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Page 5 of 16TEWL indicator (as already mentioned, doctors utilized
TEWL indicator measurement habitually on 1
st,4
th, and
7
th day). These patients presented spontaneous re-
epithelialization in very few days (2-3) days. This proto-
col induced costs and outcomes were easily detected
and omitted by the final calculations [29].
Sample size
The sample size was determined during the 1rst year of
the study as follows: The primary outcomes on which
this study was powered were hospitalization days and
the time of 50% wound healing. We had undertaken a
pilot work to estimate effect sizes. It is known that, pilot
studies offer many advantages in the estimation of an
informed effect size target for power calculations [30].
The pilot work was carried out on 50 subjects. These 50
patients were the first (randomized) patients included in
the study, so the study started, and then during the pro-
cess it was decided on how many patients were still
needed.
According to this work, MEBO substantially reduced
the in hospital stay duration by 1.7 days in average (sd:
2.7). That is, with a 2-sided test of 5% the study has
more than 90% power to detect a significant difference
in hospitalization duration, given a sample size of 100 in
each group.
Additionally, MEBO substantially reduced the time of
50% wound healing in the case of superficial partial
thickness burns (n = 30) by 2.9 days in relation to the
standard therapy (sd: 3.4) That is, with a 2-sided test of
5% the study has more than 90% power to detect a sig-
nificant difference in time of wound healing, given a
sample size of 50 in each group.
Statistical Analyses
Patient characteristics, costs and outcome variables
Statistical tests of homogeneity for the different patient
characteristics (e.g. gender, age, type of burns, skin
photo type, burn surface area, TEWL at the 1rst day,
toxic habits, co-morbidity etc), as well as for intermedi-
ate outcomes were used (c
2 test variables t-test and
Mann Whitney test for non normal data). All analyses
were made according to the intention to treat principle.
Incremental Cost Effectiveness Ratio
Fieller’s method was used to construct confidence inter-
vals for the final outcomes in the case of total groups
and superficial partial thickness burns groups. This
method takes into account the potential asymmetry of
the estimator of the ratio [31-34]. In the majority of
existing research, it presented better performances than
the other comparable methods and produced reasonably
accurate confidence intervals [29].
Fieller’s theorem is based on asymptotic normality
theory:
μ C − (ICER)μ E ∼ N(0,1)
Where μ C and μ E are respectively the means of
ΔμC and ΔμE.
Fiellers confidence intervals can be calculated as:
(ICER)
1 − z2
α/2ρcv( μC)cv( μE)
1 − z2
α.2cv( μE)
2 ± (ICER)∗
∗
zα/2

cv( μC)
2 +c v (  μE)
2−2ρcv( μC)cv( μE)-z
2
α/2(1 − ρ2)cv( μC)
2cv( μE)
2
1 − z2
α/2cv( μE)
2
Where r is the correlation coefficient for cost and
effect differences and cv respectively the coefficient of
variation.
The normality assumption of the sample means of
cost and effectiveness seemed to be reasonable in our
case. As can be seen by the relative normal quantile
plots (Q-Q) in Figure 2 where each observed value
was plotted against the expected value from the nor-
mal distribution, the points in all cases clustered
approximately around a straight line. Also, scatter-
plots in Figure 3 gave us clear indication that cost
and effect differences related to a linear function in
all groups.
The acceptability criterion was used in the case of
deep partial thickness burns group since the ICER
denominator in this case wasn’t statistically significant
[35]. Cost Effectiveness Acceptability Curves (CEAC’s),
measured the probability that the CE ratio-resulting
from a trial was acceptable in relation to different values
of the ceiling ratio (from 0 to ∞).
The cost effectiveness acceptability curve was con-
structed by calculating the proportion of 2,500 bootstrap
replications [35]. All analyses were conducted in SPSS
and Excel Professional 2003.
Results
Patient’s characteristics
Table 3 presents demographic and medical characteris-
tics of the sample. Statistical tests of homogeneity for
the different patient characteristics (e.g. gender, age,
type of burns, photo-type, burn surface area, TEWL at
the 1st day, toxic habits etc), as well as for intermediate
outcomes were used (c
2 test, t-test and Mann Whitney
test for non normal data).
Patients of all groups had similar characteristics con-
cerning the most important parameters such as burn
size (p > 0.5 in all cases) and age (p > 0.5 in all cases).
Exceptions were the cases of gender where the homoge-
neity was rejected (p = 0.04) for the superficial partial
thickness burns groups.
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Page 6 of 16Final outcomes: gain in days of in-hospital stay, days
needed for 50% wound healing
Significant differences were observed between MEBO
and the standard therapy (p = 0.03) in effectiveness in
total groups and in superficial partial thickness burn
groups. MEBO further reduced by nearly 1 day (sd: 4.5)
in average the in-hospital stay in relation to the standard
therapy. This means it reduced the hospitalization time
 
      
Figure 2 Q-Q plots of costs and effectiveness for MEBO group and standard therapy group.
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Page 7 of 16by nearly 20.6% (mean gain in days: 3.63, sd: 2.19 versus
mean: 3.01, sd: 2.02). We have to underline at this point
that this difference concerned moderate burn wounds
(TBSA < 15%) needing conservative therapy that implies
or otherwise dictates short times of hospitalization (≤ 10
days). So, the clinical significance of this find had to be
evaluated by taking into account these special circum-
stances [27]. Also, MEBO was more effective than the
standard therapy in the case of superficial partial burn
wounds since: 1. It nearly reduced by 1 day (sd: 5.05) in
average the in- hospital stay, that is it significantly
reduced (p = 0.02) the hospitalization time by 29.63% in
relation to the standard therapy (mean gain in days:
4.20, sd:2.1 versus mean:3.24, sd: 2.1). 2. It significantly
reduced (p = 0.00) the time of 50% wound healing by 2
days in average in relation to the standard therapy
group. That is, the time of 50% wound healing was
shorter by 19.07% in relation to the standard therapy
group (8.7 days, sd: 3.0 versus 10.75, sd: 3.8). On the
contrary, in the case of deep partial thickness burns the
differences observed in favor of MEBO group (mean
gain in hospitalization stay: 3.02 days sd 2.1 versus 2.79
days sd 1.9) were not statistically significant. (p = 0.56).
Cost results
Table 4 gives an overview of the mean costs for each
group. For each group, we concluded the following:
1. Total groups: MEBO presented lower total cost per
patient (although not significantly different: p = 0.10).
The mean cost per patient was nearly by 36.55 € lower
in the MEBO group. Significant differences in favor of
the MEBO group were observed in the case of the mean
 
 
--  
Figure 3 Scatter plots of Incremental costs and effectiveness for total groups, groups with deep partial thickness burs and groups
with superficial partial thickness burns.
Carayanni et al. BMC Complementary and Alternative Medicine 2011, 11:122
http://www.biomedcentral.com/1472-6882/11/122
Page 8 of 16cost of medical visits per patient (€5.31 versus €5.96, p =
0.01), hospitalization costs (€463.5 versus €512.22, p =
0.02) and costs of analgesics (€0.09 versus €016, p =
0.00). On the contrary, the mean cost of inflammatory
medicines consumed by the MEBO group was signifi-
cantly different from 0 (p = 0.00) and the mean cost of
local agents was significantly higher in the MEBO group
(€20.96 versus €11.40, p = 0.00). All other differences in
partial costs were not significant. We have to mention
also that the MEBO group presented an observed cost-
lier consumption of antibiotics (mean: 33.91 versus
mean: 31.41) not proved, nevertheless statistically signif-
icant (p = 0.09).
2. Deep partial thickness groups: Although the mean
cost per patient was lower in the MEBO group these
differences were not statistically significant (€579.83 ver-
sus €582.15, p = 0.938). The mean cost of analgesics
was higher in the standard therapy group and this dif-
ference was statistically significant (€0.08 versus €0.13, p
= 0.002). On the other hand, the cost of inflammatory
medicines consumed by the MEBO group was signifi-
cantly different from 0 (2.68 p = 0.00) and the cost of
local agents was significantly higher in the MEBO group
(€21.40 versus €12.28, p = 0.0). All other differences in
mean partial costs were not statistically significant.
3. Superficial partial thickness groups: The total mean
cost was significantly lower in the MEBO group (483.21
versus 551.13, p = 0.00). That is, the mean cost per
patient was nearly by €67.92 lower in the MEBO group
than in the standard therapy group. Highly significant
differences in favor of MEBO group were observed in
the case of medical visits (€4.28 versus €5.67, p = 0.00)
hospitalization costs (418.48 versus 496.25, p = 0.01)
and costs of analgesics (€0.10 versus €0.18 p = 0.00). On
the contrary, the MEBO group received a quantity of
inflammatory agents significantly different from 0 (p =
0.00) and the cost of local agents was significantly
higher in the MEBO group (€20.55 versus €10.63, p =
0.00). All other differences observed in mean partial
costs were not significant.
No significant differences were observed (p > 0.05 in
all cases) between groups and subgroups on the time
spent per course of treatment by doctors and nurses.
Incremental cost effectiveness
The results are as follows:
Table 3 Patient’s characteristics and homogeneity tests
MEBO GROUP STANDARD THERAPY GROUP
Total group Deep partial
thickness
Superficial
thickness
Total
groups
Deep partial
thickness
Superficial
thickness
Total
groups
Deep partial
thickness
Superficial
thickness
Patients 104 50 54 107 52 55
Gender Men: 60
Women: 44
Men: 30
Women: 20
Men: 30
Women: 24
Men: 71
Women: 36
Men: 30
Women: 22
Men: 41
Women: 14
c
2 = 3.012
p = 0.08
c
2 = 0.126
p = 0.722
c
2 = 0.423
p: 0.04
Age
(sd)
Mean: 42.62
(13.32)
Mean: 40.32
(13.3)
Mean: 44.74
(13.92)
Mean: 42.74
(14.58)
Mean: 43.94
(15.16)
Mean: 41.35
(13.08)
t-test
-0.06
p = 0.949
t-test -1.28
p = 0.204
t-test -1,33
p = 0.184
A g e > 6 0 1 57 8 1 69 7Ζ = 0.012
p = 0.49
Ζ = 0.211
p = 0.42
Ζ = 0.100
p = 0.46
Photo-type I: 1
II: 17
III: 69
IV: 17
Ι:1
II: 8
III: 35
IV: 6
I: 0
II: 9
III: 34
IV: 11
I: 2
II: 21
III: 71
IV: 13
I: 2
II: 11
III: 34
IV: 5
I: 0
II: 9
III: 38
IV: 8
c
2 = 1.27
p = 0.740
c
2 = 0.687
p = 0.744
c
2 = 1.24
p = 0.761
Toxic
habitudes
Smoking: 30
Alcohol 10
Both 3
Smoking: 18
Alcohol 4
Both 1
Smoking: 12
Alcohol 4
Both 2
Smoking: 40
Alcohol 4
Both 1
Smoking: 25
Alcohol 0
Both 0
Smoking: 15
Alcohol 4
Both 1
Ζ = 0.47
p > 0.05
Ζ = 1.01
p > 0.05
Ζ = 0.98
p > 0.05
Type of
burns
Flame: 56
Scald: 48
Flame: 27
Scald: 23
Flame31
Scald: 23
Flame: 57
Scald: 50
Flame: 26
Scald: 26
Flame31
Scald 24
c
2 = 1.075
p = 0.576
c
2 = 1.24
p = 0.761
c
2 = 2.22
p = 0.37
TEWL at the
1st day
Median: 59
IQR: 27
Median: 75
IQR: 12. 5
Median: 48
IQR: 12.25
Median: 51
IQR: 15
Median: 69
IQR: 17
Median: 51
IQR: 4
U = 5,387
p = 0.688
U = 859
p = 0.003
U = 1,.250
p: 0.135
Allergies Penicillin: 2
Grass: 3
Food 2
Penicillin: 2
Grass1
Food: 0
-
Grass: 2
Food: 2
Unknown: 4
Grass: 1
Food: 3
Unknown: 2
Grass: 1
Food: 1
Unknown: 2
Food: 2
Z = 0.5
p > 0.05
Z = 0.96
p > 0.05
Z = 0.85
p > 0.05
Burn Surface
Area (sd)
Mean: 10.26
(4.37)
Range: 5-15
Mean: 9.74
(4.84)
Range: 5-15
Mean: 10.74
(3.87)
Median: 10
Range: 5-15
Mean: 9.89
(4.89)
Range: 5-15
Mean: 10.04
(4.59)
Range: 5-15
Mean: 9.75
(3.87)
Median: 10
Range: 5-15
t = 0.53
p = 0.59
t = -0.4
p = 0.70
U: = 1,242.5
p = 0.70
Nationality Greek: 75
Third World:
12
Ex-eastern: 17
Greek: 38
Third World: 5
Ex-eastern: 7
Greek: 37
Third World:
7
Ex-eastern: 10
Greek: 69
Third World:
23
Ex-eastern: 15
Greek: 35
Third World: 8
Ex-eastern: 9
Greek: 34
Third World:
15
Ex-eastern: 6
c
2 = 4.73
p = 0.09
c
2 = 1.48
p = 0.476
c
2 = 4.02
p = 0.134
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Page 9 of 161. Total groups. The corresponding ICER is €-58.95 per
day of hospitalization gained which has a Fieller’sc o n f i -
dence interval (CI) of (-63.10;-55.09) that indicates MEBO
was more cost effective therapy than the standard therapy.
Nevertheless these results must be interpreted with cau-
tion because of the non significance of the numerator.
Deep partial thickness burns group. The correspond-
ing ICER was €-10.1 per day of hospitalization gained
which had a 95% bootstrap confidence interval, (based
on the 2.5th and 97.5th percentile of the distribution of
the 2, 500 bootstrapped ICERs), of (-120.4; 181.8), indi-
cating a large amount of stochastic uncertainty. The
acceptability curve (Figure 4) cut the y-axis at 0.51
b e c a u s eo n l y5 1 %o ft h ed e n s i t yi n v o l v e dc o s ts a v i n g s
and asymptotes to 0.54 because 54% of the density
involved health gains by the use of the MEBO therapy
Table 4 Mean costs, sd and incremental costs (in 2006 €)
MEBO STANDARD THERAPY Differences and sd
Mean costs and sd Total
groups
Deep
partial
thickness
burns
Superficial
partial
thickness
burns
Total
groups
Deep
partial
thickness
burns
Superficial
partial
thickness
burns
Total
groups
Deep
partial
thickness
burns
Superficial
partial
thickness
burns
Hospitalisation 463.5
163.35
512.12
155.10
418.48
159.11
512.22
148.45
529.11
141.12
496.25
154.65
-48.72
155.63
-16.99
146.7
-77.77
158.17
Antibiotics 33.91
29.70
34.29
29.43
33.56
30.23
31.41
16.42
29.93
12.8
32.80
19.25
2.5
23.84
4.36
22.3
0.76
25.5
Laboratory tests 0.70
2.53
0.94
2.92
0.48
2.1
0.63
2.45
0.80
2.81
0.47
2.08
0.07
2.48
0.14
2.84
0.01
2.1
Anti-inflammatory/anti-
histaminic
0.61
1.92
0.92
2.33
0.33
1.41
0.00 0.00 0.00 0.61
1.35
0.92
1.61
0.33
1.00
Scrub products 2.24
1.01
2.38
1.01
2.12
1.01
2.46
1.06
2.47
0.95
2.44
1.17
-0.22
1.04
-0.09
0.97
-0.32
1.10
Visits 5.31
2.06
6.42
1.92
4.28
1.61
5.96
1.85
6.27
1.19
5.67
2.28
-0.65
1.95
0.15
1.57
-1.39
1.99
Analgesics 0.09
0.07
0.08
0.06
0.10
0.07
0.16
0.09
0.13
0.07
0.18
0.09
-0.07
0.07
-0.05
0.06
-0.08
0.08
Local agents 20.96
2.96
21.40
3.50
20.55
2.31
11.40
3.31
12.28
3.14
10.63
3.32
9.56
3.14
9.12
3.30
9.92
2.89
Mean time spent by
doctors and nurses per
course treatment
15.66
(2.98)
16.10
(2.86)
15.26
(3.05)
14.91
(2.93)
15.61
(2.79)
14.25
(2.93)
0.75
(5.43)
0.49
(2.4)
1.01
(5.26)
Total costs* 529.66
172.75
579.83
157.70
483.21
174.44
566.21
151.45
582.15
142.28
551.13
159.47
-36.55
161.94
-2.32
148.6
-67.92.
168.42
* Mean time spent by doctors and nurses per course of treatment not included. Numbers may not add up due to rounding.
0,52 0,54 0,54 0,54 0,54 0,54 0,54 0,54 0,54 0,54 0,54
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Figure 4 Cost effectiveness acceptability curve MEBO vs. standard therapy (groups with deep partial thickness burns).
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Page 10 of 16[34]. As can be seen, beyond € 1,000 the acceptability
curve became flat and was then fairly insensitive to
Willingness to pay (WTP) levels. This indicated that a
decision-maker’sc h o i c ea tW T P€ 1,000 and over was
probably not surrounded by much uncertainty, even
when the ICERs had broad confidence intervals.
2. Superficial partial thickness burns group. MEBO
was the dominant therapy under the point of view of
the gain in hospitalization stay (ICER: €-70.75 per day of
hospitalization gained, 95% CI:-74.24;-67.58), as well as
under the point of view of TEWL (mean ICER: €-33.16
per day of recovery gained: 95%CI: -34.49;-31.89).
MEBO presented in both cases superior effectiveness at
a lower total cost.
Intermediate outcome results: pain, complications, no
healthy appearance of burn limits
A greater proportion of patients in the standard therapy
group received paracetamol (95.3% versus 84.3%) as well
as paracetamol+codeine (48.6% versus 30.77%). Also, the
standard therapy group in total groups and in superficial
partial thickness group received a greater quantity of
paracetamol (total groups: median: 3,750, IQR:5300,
superficial partial thickness group (median: 4,750,
IQR:3,200) than the MEBO therapy group (total groups:
median:1500, IQR:1463,5, superficial partial thickness
group: median:2,500, IQR:2,250). These differences were
both highly significant (p = 0.00). Also, the standard
therapy group in total groups and in superficial partial
thickness group received a significantly greater (p =
0.00) quantity of paracetamol+ codeine (total groups:
median:2,700 IQR:1,463, superficial partial thickness
group: median:2,700, IQR: 1,687) than the MEBO group
(total groups: median:1125, IQR:900, superficial partial
thickness group: median:900, IQR:2,250).
In the case of deep partial thickness burns highly sig-
nificant differences were observed in the case of parace-
tamol with the standard therapy group presenting a
higher consumption of paracetamol (median:2,750,
IQR:1,687) than the MEBO group (median:900,
IQR:2,250). Nevertheless, no significant differences were
observed in the consumption of paracetamol + codeine
between these groups (p = 0.05).
Figure 5 shows the median pain profiles for the morn-
ing, afternoon and evening assessments respectively, for
the first 12 days. In the first days of therapy, the profile
was more similar for the 2 treatment groups, whereas
the median pain scores are significantly lower for
MEBO (p = 0.00) after approximately the 2
nd post burn
day in the morning or the 3
rd day in the evening with
no major differences between the treatment groups after
the 8
th post burn day.
11 out of 104 patients in MEBO group versus 8 out
107 patients in the standard therapy group presented
complications (Figure 6). These differences aren’ts t a t i s -
tically significant (p = 0.07). Five patients on the MEBO
g r o u p( 3f r o md e e pp a r t i a lt h i c k n e s sb u r n sg r o u pa n d2
from superficial partial thickness burns group) presented
mild allergic reaction. During the period of the allergy
Dimethindene cream was prescribed to these patients
for 6 το 7 days whereas one patient received additionally
methylprednisonole.
The incidence of wound infection (Staphylococcus,
Pseudomonas) was similar (p = 0.62) in the 2 groups.
Pseudomonas was more frequently presented in MEBO
patients (4 out of 6 patients) than in the standard ther-
apy group (3 out of 8 patients), although Staphylococcus
wound infection was more frequent in the standard
therapy group (5 out of 8 patients versus 2 out of 6
patients in the MEBO group). We have to note that the
higher prevalence of Pseudomonas pathogen in the
MEBO group can explain the observed higher costs
(although not significantly different) in antibiotics con-
sumption in this group in relation to the standard ther-
apy group.
38 out of 104 patents and 28 out of 107 presented no
healthy appearance of burn limits for some days (Figure
6). These differences aren’t significant (p = 0.10). In the
case of deep partial thickness burns, 20 out of 50 for
MEBO group versus 13 out of 52 for the standard ther-
apy presented no healthy appearance of burn limits for
some days, but these differences are not significant (p =
0.10). Finally, in the case a of the superficial partial
group 18 out of 54 in the MEBO group versus 15 out of
55 in the standard therapy group presented no healthy
appearance of burn limits for some days although these
differences aren’t statistically significant (p = 0.49).
The median time of no healthy appearance, (Figure 7),
was shorter in the standard therapy group (total groups),
that is 5 days (IQR:5) versus 6 days (IQR: 5) for the
MEBO group although these differences are not statisti-
cally significant (p = 0.29). No significant differences
were observed in the median time of no healthy appear-
ance of the burn limits in deep partial thickness burn
groups (p = 0.44). Nevertheless, this time was shorter in
the standard therapy group (median: 5.00, IQR:5) than
in the MEBO group, (median:7.00, IQR: 4). On the con-
trary, in the groups with superficial-partial thickness
burns the median time of no healthy appearance was
significantly shorter in the MEBO group (median:4.00,
IQR:5.25) than in the standard therapy group (med-
ian:5.00, IQR:3) and this difference was statistically sig-
nificant (p = 0.02).
Sensitivity analysis
The above analyses were repeated for the hypothetical
scenarios of discounting costs and outcomes by 3%
and 5% because of the unfavourable economic
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Page 11 of 16situation in the country and the increased deficiencies
in nursing personnel. Table 5 summarizes the results
of sensitivity analysis. As can be seen, the analyses did
not reverse the findings. Figure 8 presents the cost
effectiveness acceptability curves corresponding to
three different discount rates for effectiveness in the
case of deep partial thickness burn groups. As can be
seen, beyond the WTP ceiling of €1,000 the acceptabil-
ity continued to be fairly insensitive to WTP levels.
57% up to 61% of the joint density involves monetary
gains and 53% up to 54% of the joint density involves
health gains by the use of MEBO, under the different
scenarios described in Figure 8. Nevertheless, we have
to underline that uncertainty remains particularly
 
 
 
 
Figure 5 Median daily pain (morning and evening) for total groups, groups with deep partial thickness burs and groups with
superficial partial thickness burns.
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Page 12 of 16important in this case and these indications should be
interpreted with caution.
Discussion
In the total groups MEBO presented lower cost
(although not significantly different: p = 0.10) and better
effectiveness. That is, this randomized trial supported
the hypothesis that MEBO reduces the time of hospitali-
zation. The effectiveness results were consistent with
the results of previous studies [10-16]. Also, the data
suggest that MEBO was the dominant therapy for super-
ficial partial thickness burns with significantly lower
costs and significantly superior effectiveness due to a
lesser time of recovery. In this case the results support
the corresponding hypotheses i and ii that MEBO
reduces the time of hospitalization and wound healing
as well as the costs of recovery. On the contrary, no
Figure 6 Distribution of total groups by complication
appearance.
Figure 7 Time of no healthy appearance of burn limits (total groups).
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Page 13 of 16significant differences were observed in cost and effec-
tiveness in the case of deep partial thickness burns
group, so in this case the data do not support the above
mentioned tested hypotheses. Also, results in all groups
suggest that MEBO reduces pain levels and presents
similar percentages of complications with the compara-
tor, supporting the corresponding hypotheses iii and iv
of this study.
Some limitations of this study were found to merit
discussion:
The major limitation of this study is that it was single
centred. Nevertheless, the setting was representative of
the usual care in Greece and the sample was representa-
tive of the patients hospitalized for burns. (The annual
burn sample of the specific area in our study exceeded
10% of the total potential eligible population, a fact that
may assure the external validity of the study).
Second, the statistical power was inadequate (1-b =0 .
14) in the case of deep partial thickness burn groups to
detect significant differences. Nevertheless, it did not
threaten the external -validity of the study, which was
designed for the total number of patients with TBSA <
15%.
Third, the follow-up of this study was rather short (18
days). Nevertheless, other studies concurred with our
results and found that scar quality was superior in
wounds treated with MEBO [10,11,15,16].
Fourth, although the design of this study was pragma-
tically oriented, protocol induced costs and outcomes
were observed. These protocol induced costs and out-
comes were easily detected and were omitted. Neverthe-
less, as protocol induced costs and outcomes have
appeared it may be difficult or impossible to exclude the
full impact of these services of the analysis and this
could bias the final differences [36]. On the other hand,
in-hospital stay constitutes a more pragmatic but also
subjective measure of effectiveness. Also, the research
was not blinded because Povidone Iodine has a charac-
teristic odour and colour and was therefore recog-niz-
able. An unblinding trial could be highly susceptible to
Table 5 Results of sensitivity analysis (Total groups and superficial partial thickness burns)
Discount rate Groups ICER and Fieller’sC I
Gain in days of hospitalisation Gain in days of recovery (TEWL)
3% Total groups -60.72 (CI:-64.92;-56.76) to -57.23
(CI-53.48;-61.19)
_
3% Groups with superficial partial thickness burns -73,04(CI-78.14;-68.55) to -68.70
(CI-73.34;-64.58)
-34.13 (CI:-35.07;-33.21) to -32.17 (CI:-33.51;-30.93)
5% Total groups -61.95 (CI:-66.27;-57.88) to -56.14 CI:
(-60.67;-52.41)
_
5% Groups with superficial partial thickness burns -74.64 (-79.97;-69.96) to -67.38
(-71.93;-63.34)
-34.83 (CI:-36.24;-33.46) to -31,56(CI:-32.43;-30.48)
0,613
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Figure 8 Cost effectiveness acceptability curves for deep partial thickness burns (discount rates: 0%,3%, 5%).
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Page 14 of 16classification bias [26,35]. Nevertheless, the persons eval-
uating treatment outcomes were blinded to treatment
group assignment in order to eliminate classification
bias [37].
Fifth, there was a general problem in the cost effec-
tiveness studies of local agents because of the inconclu-
sive evidence regarding the efficacy of local agents on
burn wounds [37]. A trial based evaluation such as the
described could lead to erroneous conclusions for it
may prove a therapy as cost effective simply because the
comparator is completely ineffective. In this study this
inconclusive evidence can be accelerated by the fact that
the comparator was a known cytotoxic agent [38] with
deleterious effects in wound to the keratinocytes and
fibroblasts. Nevertheless in Greece up to this day Povi-
done Iodine is the first line treatment modality for burns
of this kind essentially because of its antimicrobial
effects [39].
Finally, the sensitivity analysis compared the actual
situation with some hypothetical scenarios that were
somewhat arbitrary, and the trade-offs between costs
and effects may have been different from what was pre-
s e n t e d .A p p e a r a n c eo fa l l e r g yo ns o m ep a t i e n t so ft h e
MEBO group as well as the higher prevalence in this
group of Pseudomonas pathogens needs also further
exploration.
Conclusions
Results suggest that topical application of MEBO may be
considered for further investigation as a potential first-
line treatment modality for superficial partial thickness
burns. MEBO, in this case, presents similar percentages
of complications with the comparator, lower pain levels
and shorter time of no healthy appearance of the burn
limits. Also, it constitutes the dominating therapy based
on cost effectiveness aggregation. Nevertheless, in light
of the above mentioned limitations our findings should
be interpreted with some caution and must be verified
in a larger multi-center trial. It is our recommendation
that such a trial should be conducted in the near future.
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